会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 14. 发明申请
    • PERIPHERALLY RESTRICTED FAAH INHIBITORS
    • 外用限制性FAAH抑制剂
    • WO2012015704A2
    • 2012-02-02
    • PCT/US2011045114
    • 2011-07-22
    • UNIV CALIFORNIAUNI DEGLI STUDI DI URBINO CARLO BOUNIV PARMAPIOMELLI DANIELECLAPPER JASON RMORENO-SANZ GUILLERMODURANTI ANDREATONTINI ANDREAMOR MARCOTARZIA GIORGIO
    • PIOMELLI DANIELECLAPPER JASON RMORENO-SANZ GUILLERMODURANTI ANDREATONTINI ANDREAMOR MARCOTARZIA GIORGIO
    • C07C271/56A61K31/27A61P29/00A61P37/00
    • C07C271/56C07C2601/14
    • Peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH) are provided. The compounds can suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). Despite their relative inability to access brain and spinal cord, the compounds attenuate behavioral responses indicative of persistent pain in rodent models of inflammation and peripheral nerve injury, and suppresses noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CBi receptor blockade prevents these effects. Accordingly, the invention also provides methods, and pharmaceutical compositions for treating conditions in which the inhibition of peripheral FAAH would be of benefit. The compounds of the invention are according to the formula (I): in which R1 is a polar group. In some embodiments, R1 is selected from the group consisting of hydroxy and the physiologically hydro lysable esters thereof. R2 and R3 are independently selected from the group consisting of hydrogen and substituted or unsubstituted hydrocarbyl; each R4 is independently selected from the group consisting of halogen and substituted or unsubstituted hydrocarbyl and n is an integer from 0 to 4; each R5 is independently selected from the group consisting of halo and substituted or unsubstituted hydrocarbyl and m is an integer from 0 to 3; and R6 is substituted or unsubstituted cyclohexyl; and the pharmaceutically acceptable salts thereof.
    • 提供脂肪酸酰胺水解酶(FAAH)的外周限制性抑制剂。 该化合物可以抑制FAAH活性,并增加中枢神经系统(CNS)外的氨基酰胺水平。 尽管它们相对不能进入脑和脊髓,但化合物减弱了指示炎症和周围神经损伤的啮齿动物模型中的持续疼痛的行为反应,并且抑制了牵连伤害性处理的脊髓区域中的有害刺激诱发的神经元激活。 CBi受体阻断防止这些影响。 因此,本发明还提供了用于治疗其中外周FAAH的抑制将是有益的病症的方法和药物组合物。 本发明的化合物是根据式(I):其中R 1是极性基团。 在一些实施方案中,R 1选自羟基及其生理上可水解的酯。 R2和R3独立地选自氢和取代或未取代的烃基; 每个R 4独立地选自卤素和取代或未取代的烃基,n是0至4的整数; 每个R 5独立地选自卤素和取代或未取代的烃基,m是0-3的整数; 并且R 6是取代或未取代的环己基; 及其药学上可接受的盐。
    • 16. 发明申请
    • COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES OF OLEOYLETHANOLAMIDE-LIKE COMPOUNDS AND MODULATORS OF PPARα
    • 化合物,组合物和治疗用途的乙酰氨基酚类化合物和PPARα的调节剂
    • WO2005002524A2
    • 2005-01-13
    • PCT/US2004/021394
    • 2004-07-01
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIAFU, JinGAETANI, SilvanaPIOMELLI, Daniele
    • FU, JinGAETANI, SilvanaPIOMELLI, Daniele
    • A61K
    • A61K31/20
    • The present invention provides compounds, compositions, and methods for the treatment of disorders and conditions mediated by PPARa. The invention relates to the surprising discovery that oleoylethanolamide (OEA) is an endogenous high affinity and selective ligand of PPARa. The compounds of the invention include, but are not limited to, specific PPARa agonists sharing the receptor binding properties of OEA and fatty acid alkanolamides and their homologs which also are PPARa agonists. Such OEA-like compounds include, but are not limited to, compounds of the following formula: in which n is from 0 to 5, the sum of a and b can be from 0 to 4; Z is a member selected from the group consisting of -C(O)N(Ro) ; (Ro)NC(O) ; OC(O) ; (O)CO ; O; NRo; and S; and wherein Ro and R2 are members independently selected from the group consisting of unsubstituted or unsubstituted alkyl, hydrogen, C1 -C6 alkyl, and lower (C1-C6) acyl, and wherein up to eight hydrogen atoms are optionally substituted by methyl or a double bond, and the bond between carbons c and d may be unsaturated or saturated, or a pharmaceutically acceptable salt thereof.
    • 本发明提供了用于治疗由PPARα介导的病症和病症的化合物,组合物和方法。 本发明涉及令​​人惊奇的发现,即油基乙醇酰胺(OEA)是PPARα的内源性高亲和力和选择性配体。 本发明的化合物包括但不限于分享了OEA和脂肪酸链烷醇酰胺及其同系物的受体结合性质的特异性PPARα激动剂,它们也是PPARα激动剂。 这种OEA类化合物包括但不限于下式的化合物:其中n为0至5,a和b的和可以为0至4; Z是选自-C(O)N(Ro); (Ro)NC(O); OC(O); (O)CO; O; NRO; 和S; 并且其中R a和R 2是独立地选自未取代或未取代的烷基,氢,C 1 -C 6烷基和低级(C 1 -C 6)酰基的成员,并且其中多达8个氢原子任选地被甲基或双 碳和c之间的键可以是不饱和的或饱和的,或其药学上可接受的盐。
    • 17. 发明申请
    • MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS
    • 丙二酰胺水解后阻塞的焦虑调节
    • WO2004033422A2
    • 2004-04-22
    • PCT/US2003/031844
    • 2003-10-07
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIAPIOMELLI, DanieleDURANTI, AndreaTONTINI, AndreaMOR, MarcoTARZIA, Georgio
    • PIOMELLI, DanieleDURANTI, AndreaTONTINI, AndreaMOR, MarcoTARZIA, Georgio
    • C07D
    • C07C311/29C07C271/56C07C275/54C07C2601/14C07D209/08C07D211/06C07D215/06C07D307/79C07D487/04
    • Fatty acid amide hydrolase inhibitors of the Formula (I) are provided, wherein X is NH, CH 2 , O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R 1 and R 2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R 1 and R 2 is absent, and that, if Z is N, optionally R 1 and R 2 may optionally be taken together to form a substituted or unsubstituted N -heterocycle or substituted or unsubstituted heteroaryl with the N atom to which they are each attached. Pharmaceutical compositions comprising the compounds of Formula (I) and methods of using them to inhibit FAAH and/or treat appetite disorders, glaucoma, pain, insomnia, and neurological and psychological disorders including anxiety disorders, epilepsy, and depression are provided.
    • 提供了式(I)的脂肪酸酰胺水解酶抑制剂,其中X是NH,CH 2,O或S; Q是O或S; Z是O或N; R是选自取代或未取代的芳基; 取代或未取代的联苯基,取代或未取代的萘基和取代或未取代的苯基; 取代或未取代的三联苯基; 取代或未取代的环烷基,杂芳基或烷基; 且R 1和R 2独立地选自H,取代或未取代的烷基,取代或未取代的杂烷基和取代或未取代的苯基,取代或未取代的联苯基 ,取代或未取代的芳基和取代或未取代的杂芳基; 条件是如果Z是O,则R 1和R 2中的一个不存在,并且如果Z是N,则任选地R 1 1 和R 2'可以任选地一起形成取代或未取代的N - 杂环或取代或未取代的与它们各自连接的N原子相连的杂芳基。 提供了包含式(I)化合物的药物组合物和使用它们抑制FAAH和/或治疗食欲障碍,青光眼,疼痛,失眠以及神经和心理障碍,包括焦虑症,癫痫和抑郁症的方法。